Skip to main content
Premium Trial:

Request an Annual Quote

Mount Sinai to Establish Loeb Center for Alzheimer's Disease with $15M Gift

NEW YORK (GenomeWeb) — The Mount Sinai Health System today announced that it has received a gift of $15 million from Daniel and Margaret Loeb to establish a new center for Alzheimer's disease research.

The new center, named in memory of Daniel Loeb's father Ronald, will support a network of research programs and related clinical initiatives across the Mount Sinai Health System focused on catalyzing genomic and other biology research in Alzheimer's disease.

Molecular geneticist and neuropsychiatric researcher Alison Goate will lead the new center in collaboration with Mount Sinai faculty members Mary Sano, Sam Gandy, and Eric Schadt. The Loeb center will also interact with several other Mount Sinai groups, most importantly its Alzheimer's Disease Research Center.

Mount Sinai President and CEO Kenneth Davis said in a statement that the Loebs' gift will have an "enormous positive effect on [Mount Sinai's] ability to bring together [its] core competencies in Alzheimer's disease research: genomics, bioinformatics, imaging, and clinical trials."

Goate, "one of the chief architects of the genomics revolution in Alzheimer's disease," according to Davis, has identified some of the key gene mutations associated with heritable risk for the disease, including a rare mutation in the PLD3gene that doubles the risk of developing late onset Alzheimer's disease. 

She also led the largest ever genome-wide association study of protein markers for Alzheimer's in patients' cerebrospinal fluid, discovering three new genetic variants that may identify the presence of the disease.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.